Home Newsfeeds Piper Sandler Reinstates Overweight on FVCBankcorp, Announces $22 Price Target

Piper Sandler Reinstates Overweight on FVCBankcorp, Announces $22 Price Target

Piper Sandler analyst Casey Orr Whitman reinstates FVCBankcorp (NASDAQ:FVCB) with a Overweight and announces $22 price target.

byBenzinga Newsdesk

December 5, 2022

1 minute read

Piper Sandler analyst Casey Orr Whitman reinstates FVCBankcorp (NASDAQ:FVCB) with a Overweight and announces $22 price target.

Longeveron Provides Corporate Update And Announces 2023 Strategic Priorities And Anticipated Milestones

By Benzinga Newsdesk

January 6, 9:34 AM

– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE

LGVN

Geron Announces Upcoming Oral Presentation At 2023 American Society Of Clinical Oncology Annual Meeting Of Imetelstat Data From IMerge Phase 3 Lower Risk MDS Trial

By Happy Mohamed

April 26, 10:06 AM

Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company's first-in-class telomerase inhibitor,

GERN

What’s Going On With Okta Stock Thursday?

By Anusuya Lahiri

February 1, 2:07 PM

Okta, Inc (NASDAQ: OKTA) announced a restructuring plan to improve efficiency, leading to a 7% reduction in workforce and $24 million in charges. Other tech companies also experienced layoffs in early 2024.

AMZN

$10 Million Bet On NortonLifeLock? 4 Stocks Insiders Are Buying

By Lisa Levin

September 21, 9:31 AM

Although US stocks closed lower on Tuesday, there were a few notable insider trades.

BRZE

Piper Sandler Reinstates Overweight on FVCBankcorp, Announces $22 Price Target

Related Posts

Longeveron Provides Corporate Update And Announces 2023 Strategic Priorities And Anticipated Milestones

Geron Announces Upcoming Oral Presentation At 2023 American Society Of Clinical Oncology Annual Meeting Of Imetelstat Data From IMerge Phase 3 Lower Risk MDS Trial

What’s Going On With Okta Stock Thursday?

$10 Million Bet On NortonLifeLock? 4 Stocks Insiders Are Buying